A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.

BACKGROUND Mutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer. PATIENTS AND METHODS Eleven members of an Eastern Finnish family with multiple cases of breast and ovarian cancers were screened for BRCA1/2 mutations using protein truncation test (PTT), conformation-sensitive gel electrophoresis (CSGE) and sequencing. RESULTS Five of the six BRCA2 4088insA mutation carriers were affected. Mutation-positive breast/ovarian cancer patients had an excellent response to treatment even when prognosis as assessed by classical factors was poor. CONCLUSION The 4088insA mutation appears to be associated with a favourable clinical course of breast and ovarian cancer, providing an informative example on the role of an individual mutation in assessing the prognosis for mutation carriers. Our results encourage more research on the effects of an individual mutation on clinical characteristics, response to treatment and outcome.

[1]  A. Mannermaa,et al.  Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families , 2007, Clinical genetics.

[2]  Anssi Auvinen,et al.  BRCA2 mutations in 154 finnish male breast cancer patients. , 2004, Neoplasia.

[3]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[4]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[5]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[6]  P. Chappuis,et al.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.

[7]  P. Kyyrönen,et al.  Survival of breast cancer patients in BRCA1, BRCA2, and non‐BRCA1/2 breast cancer families: A relative survival analysis from Finland , 2001, International journal of cancer.

[8]  H. Nevanlinna,et al.  BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients , 2001, European Journal of Human Genetics.

[9]  H. Nevanlinna,et al.  BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families. , 2001, International journal of oncology.

[10]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[11]  J. Kere,et al.  Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub‐population , 2001, Genetic epidemiology.

[12]  Jaana M. Hartikainen,et al.  Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland , 2000, European Journal of Human Genetics.

[13]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[14]  Å. Borg,et al.  Prognosis and clinical presentation of BRCA2-associated breast cancer. , 2000, European journal of cancer.

[15]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Ponder,et al.  Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Cancer research.

[17]  D. W. Abbott,et al.  Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. , 1998, Journal of the National Cancer Institute.

[18]  R. Winqvist,et al.  Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. , 1998, American journal of human genetics.

[19]  A. Ashworth,et al.  A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. , 1998, British Journal of Cancer.

[20]  E. Venkatraman,et al.  BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.

[21]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[22]  O. Kallioniemi,et al.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. , 1997, Human molecular genetics.

[23]  B. Ponder,et al.  A low proportion of BRCA2 mutations in Finnish breast cancer families. , 1997, American journal of human genetics.

[24]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[25]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[26]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[27]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[28]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[29]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.